Literature DB >> 11472349

Antisense oligodeoxynucleotides to latent membrane protein 1 induce growth inhibition, apoptosis and Bcl-2 suppression in Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cells, but not in EBV-positive natural killer cell lymphoma cells.

T Noguchi1, K Ikeda, K Yamamoto, I Yoshida, A Ashiba, J Tsuchiyama, K Shinagawa, T Yoshino, M Takata, M Harada.   

Abstract

Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) is essential for immortalization of B cells by EBV, protects the infected cells from apoptotic cell death and induces Bcl-2 expression. Suppression of LMP-1 expression by antisense oligodeoxynucleotides (AS-oligo) to LMP-1 inhibits proliferation, promotes apoptosis and suppresses Bcl-2 expression in EBV-transformed B cells. However, the function of LMP-1 expression in EBV-positive natural killer (NK) cell lymphoma cells has not been reported previously. We examined the function of LMP-1 in two EBV-positive NK cell lymphoma cell lines (NK-YS and YT) through suppressing LMP-1 expression by AS-oligo to LMP-1. The AS-oligo to LMP-1 suppressed LMP-1 mRNA and protein expression in two EBV-positive NK cell lymphoma cell lines, as well as in an EBV-transformed B-cell line (CMG-1). Proliferation was inhibited, apoptosis was induced and Bcl-2 expression was suppressed in CMG-1 cells, but none of these events were observed in NK-YS or YT cells. These results suggest that proliferation, inhibition of apoptosis and Bcl-2 expression in EBV-positive NK cell lymphoma cells are not directly regulated by LMP-1 as in EBV-transformed B-cell lines, but are probably mediated through other signal transducing systems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472349     DOI: 10.1046/j.1365-2141.2001.02887.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30).

Authors:  S C Burgess; J R Young; B J G Baaten; L Hunt; L N J Ross; M S Parcells; P M Kumar; C A Tregaskes; L F Lee; T F Davison
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-08       Impact factor: 11.205

Review 2.  Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease.

Authors:  Keisei Kawa
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 3.  Epstein-barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved.

Authors:  Lindsay C George; Martin Rowe; Christopher P Fox
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

4.  Human monocytic cell lines transformed in vitro by Epstein-Barr virus display a type II latency and LMP-1-dependent proliferation.

Authors:  Eric Masy; Eric Adriaenssens; Claire Montpellier; Pascale Crépieux; Alexandra Mougel; Brigitte Quatannens; Gautier Goormachtigh; Nathalie Faumont; Fabienne Meggetto; Claude Auriault; Hervé Groux; Jean Coll
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 5.  Epstein-Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells.

Authors:  Qin Fu; Chen He; Zheng-rong Mao
Journal:  J Zhejiang Univ Sci B       Date:  2013-01       Impact factor: 3.066

Review 6.  The Modulation of Apoptotic Pathways by Gammaherpesviruses.

Authors:  Shuvomoy Banerjee; Timsy Uppal; Roxanne Strahan; Prerna Dabral; Subhash C Verma
Journal:  Front Microbiol       Date:  2016-04-27       Impact factor: 5.640

Review 7.  Molecular pathogenic pathways in extranodal NK/T cell lymphoma.

Authors:  Sanjay de Mel; Susan Swee-Shan Hue; Anand D Jeyasekharan; Wee-Joo Chng; Siok-Bian Ng
Journal:  J Hematol Oncol       Date:  2019-04-02       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.